JRCT ID: jRCT1010220025
Registered date:07/11/2022
A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Pulmonary hypertensIon in systemic sclerosis |
Date of first enrollment | 08/11/2022 |
Target sample size | 230 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Time between the first right heart catheterization and first hospitalization or death due to worsening pulmonary hypertension. |
---|---|
Secondary Outcome | 1. Change in parameters of right heart catheterization including mPAP 2. WHO functional class 3. emPHasis-10 (10 questionnaire for assessing health-related quality of life in pulmonary hypertension) 4. Six-minute walk distance 5. Plasma and serum biochemical markers including , BNP , NT-proBNP , hemoglobin , uric acid , haptoglobin , KL-6 6. Pulmonary function tests including diffusing capacity for carbon monoxide 7. Transthoracic echocardiography including tricuspid regurgitation velocity, left ventricle ejection fraction, transmitral flow velocity pattern(E, E/A ratio and deceleration time), peak velocity of early diastolic mitral annulus motion (septal e' velocity, lateral e' velocity and E/e') and left atrial volume index 8. Modified Rodnan total skin thickness score(mRSS) |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Patients who fall under 1, 2, 3, and 4 below are eligible. 1.Age 18 years or older at the time of inclusion. 2.Fulfilling 2013 ACR/EULAR classification criteria for systemic sclerosis or having scleroderma spectrum disorders (sclerodactyly or systemic sclerosis specific autoantibodies (anti-Scl-70, anti-centromere or anti-RNA polymerase III antibodies)) and fulfilling on of the following criteria;2004 MHLW classification criteria for mixed connective tissue disease,1997 ACR classification criteria for systemic lupus erythematosus, 2012 SLICC classification criteria for systemic lupus erythematosus, Bohan and Peter criteria for the diagnosis of polymyositis and dermatomyositis, or 2017 ACR/EULAR classification criteria for primary Sjogren's syndrome. 3.Having had first right heart catheterization later than 2015 with suspicion of PH by unexplained dyspnea,increased NT-proBNP (more than twice the upper limit of normal), reduced pulmonary diffusing capacity (DLCO <60% or FVC/DLCO >1.6),and elevated tricuspid regurgitant velocity (>2.8m/s). 4.A person who voluntarily agrees to participate in the study or who does not refuse to participate in the study. |
Exclude criteria | 1.A person who is judged by the principal investigator to be unsuitable as a research subject |
Related Information
Primary Sponsor | Kato Masaru |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Naoko Okita |
Address | North 14 West 5,Kita-ku,Sapporo,Hokkaido,060-8648 Japan Hokkaido Japan 060-8648 |
Telephone | +81-11-706-7923 |
HAPPINESS_hokudai@pop.med.hokudai.ac.jp | |
Affiliation | Research and Development Division,Clinical Research and Medical Innovation Center,Institute of Health Science Innovation for Medical Care,Hokkaido University Hospital |
Scientific contact | |
Name | Masaru Kato |
Address | North 14 West 5,Kita-ku,Sapporo,Hokkaido,060-8648 Japan Hokkaido Japan 060-8648 |
Telephone | +81-11-706-5916 |
ktmasaru@med.hokudai.ac.jp | |
Affiliation | Hokkaido University Hospital |